Shilpa Medicare Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 28 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹14.1K Cr
FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics. - European formulation business expects healthy growth, with multiple product launches planned in FY27. - Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC. - API oncology product expansion underway, with steady growth expected rather than steep increase. - NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27. - U.S. EBITDA margins are currently at 29% with ambitions to reach 35% over the next 1-2 years, though immediate achievement is uncertain due to ongoing reinvestments for growth (Page 8, 18).
From Shilpa Medicare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹815
Market Cap
₹14.1K Cr
P/E Ratio
49.6
How does Shilpa Medicare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Shilpa Medicare Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Shilpa Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹437 Cr, net profit ₹108 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics.
- →European formulation business expects healthy growth, with multiple product launches planned in FY27.
- →Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC.
- →API oncology product expansion underway, with steady growth expected rather than steep increase.
- →NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27.
- →U.S. revenues expected to grow, focusing on super specialty products despite discontinuation of some generics.
- →EBITDA margins targeted to improve toward 35% over 1-2 years as operational leverage builds with growth.
- →Licensing income expected to remain robust with pipeline visibility.
- →Polymer business expected to grow steadily, though scaling to $20 million run rate may take time.
📈 Profitability & Margins
- →EBITDA margins are currently at 29% with ambitions to reach 35% over the next 1-2 years, though immediate achievement is uncertain due to ongoing reinvestments for growth (Page 8, 18).
- →Robust growth is expected across biologics and formulations, with biologics revenue having doubled to INR150 crores in FY26 and expected to grow further driven by CDMO programs, licensing income, and biosimilar launches in FY27 and FY28 (Pages 9, 10, 18).
- →European formulation business, including products like Rotigotine and Nilotinib, is expected to see healthy growth with new product launches in FY27 and FY28, representing meaningful revenue drivers (Pages 7, 9, 16).
- →Licensing revenues are expected to sustain at similar or higher levels due to a strong pipeline of molecules and deals (Pages 8, 18).
- →ROCE improved to 17.4% in FY26 (excluding biologics investment) with expectations of further improvements as operating leverage kicks in (Pages 6, 18).
🏗️ Capital Expenditure Plans
💰 Fundraising & Capital Structure
- →The company’s interest outgo for FY26 has reduced year-on-year and is expected to stabilize at the current quarter run rate in the near future.
- →The company plans to fund its upcoming capex programs broadly via internal accruals.
- →There is no explicit mention of any new fundraising through debt or equity in the current or near future.
- →Net debt increased from INR550 crores in the previous year to INR613 crores in FY26, aligning with business growth.
- →Overall, the company appears focused on self-funding growth and capex through internal cash generation rather than external fundraising at this time.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Shilpa Medicare Ltd Q4 FY26 results?
FY27 growth outlook is positive with scaling opportunities, especially in formulation and biologics. - European formulation business expects healthy growth, with multiple product launches planned in FY27. - Biologics segment projected to grow significantly in FY27 and FY28, driven by CDMO business, licensing income, and new product launches like Nivolumab and ADC. - API oncology product expansion underway, with steady growth expected rather than steep increase. - NorUDCA product shows steep QoQ growth post-launch; further scaling expected in FY27. - U.S. EBITDA margins are currently at 29% with ambitions to reach 35% over the next 1-2 years, though immediate achievement is uncertain due to ongoing reinvestments for growth (Page 8, 18).
What is Shilpa Medicare Ltd share price analysis?
Shilpa Medicare Ltd currently shows a neutral. The stock trades at a P/E of 49.6 with a market cap of ₹14,116 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare Ltd planning capital expenditure?
FY26 capex was INR361 crores, funded primarily via internal accruals and deployed in key verticals: API, CDMO, and albumin facility.
Keep Shilpa Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.